Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico

Table 3

Cox regression analysis of overall survival (OS).

Variable	HR	IC 95%	value
Univariate analysis
Treatment
RCHOP	—
RChOP	1.717	0.884–3.335	0.110
RCOP	1.844	0.928–3.664	0.081
ECOG
1	—
2	3.478	1.929–6.269	0.000
3	5.361	2.466–11.657	0.000
Infections
None	—
Ambulatory treated	0.519	0.199–1.351	0.179
Required hospitalization	3.402	1.659–6.977	0.001
Febrile neutropenia	3.646	1.808–7.352	0.000
B symptoms
None	—
Yes	2.267	1.213–4.236	0.010
Extranodal sites
1	1.703	0.842–3.443	0.138
2	2.393	1.088–5.260	0.030
3 or more	2.039	0.802–5.182	0.134
Bulky disease
Yes	1.948	1.125–3.372	0.017
Cycles of treatment	0.642	0.573–0.720	0.000
HB mg/dL
>13
10–12.9	1.431	0.777–2.636	0.249
8–10	2.543	0.774–8.355	0.124
<8	3.196	1.320–7.737	0.010
DHL
High	2.012	1.157–3.496	0.013
Creatinine (mg/dL)	1.847	1.064–3.206	0.029
B2 microglobulin	1.196	1.061–1.350	0.003
Leucocytes	1.0001	1.00007–1.0002	0.000
Albumin (g/dL)	0.422	0.281–0.632	0.000
Age
<75	—
≥75	1.06	0.624–1.82	0.812
Multivariate analysis
Treatment
RCHOP	—
RChOP	1.354	0.655–2.798	0.413
RCOP	1.045	0.425–2.568	0.922
ECOG
1	—
2	1.862	0.900–3.853	0.093
3	3.740	1.428–9.793	0.007
Infections
None	—
Ambulatory treated	0.557	0.198–1.561	0.266
Required hospitalization	1.971	0.759–5.112	0.163
Febrile neutropenia	2.550	1.029–6.317	0.043
B symptoms
None	—
Yes	2.377	1.150–4.912	0.019
Extranodal sites
1	1.590	0.689–2.667	0.276
2	1.946	0.752–5.035	0.170
3 or more	3.637	1.269–10.422	0.016
Bulky disease
Yes	1.895	0.895–4.011	0.095
Cycles of treatment	0.600	0.513–0.702	0.000